GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » American Oncology Network Inc (NAS:AONCW) » Definitions » COGS-to-Revenue

American Oncology Network (American Oncology Network) COGS-to-Revenue : 0.97 (As of Mar. 2024)


View and export this data going back to 2023. Start your Free Trial

What is American Oncology Network COGS-to-Revenue?

American Oncology Network's Cost of Goods Sold for the three months ended in Mar. 2024 was $354.95 Mil. Its Revenue for the three months ended in Mar. 2024 was $364.34 Mil.

American Oncology Network's COGS to Revenue for the three months ended in Mar. 2024 was 0.97.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. American Oncology Network's Gross Margin % for the three months ended in Mar. 2024 was 2.58%.


American Oncology Network COGS-to-Revenue Historical Data

The historical data trend for American Oncology Network's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

American Oncology Network COGS-to-Revenue Chart

American Oncology Network Annual Data
Trend Dec20 Dec21 Dec22 Dec23
COGS-to-Revenue
0.91 0.92 0.92 0.94

American Oncology Network Quarterly Data
Dec20 Dec21 Sep22 Dec22 Mar23 Sep23 Dec23 Mar24
COGS-to-Revenue Get a 7-Day Free Trial 0.91 0.92 0.92 0.97 0.97

American Oncology Network COGS-to-Revenue Calculation

American Oncology Network's COGS to Revenue for the fiscal year that ended in Dec. 2023 is calculated as

COGS to Revenue=Cost of Goods Sold / Revenue
=1196.389 / 1279.185
=0.94

American Oncology Network's COGS to Revenue for the quarter that ended in Mar. 2024 is calculated as

COGS to Revenue=Cost of Goods Sold / Revenue
=354.948 / 364.339
=0.97

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


American Oncology Network  (NAS:AONCW) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

American Oncology Network's Gross Margin % for the three months ended in Mar. 2024 is calculated as:

Gross Margin %=1 - COGS to Revenue
=1 - Cost of Goods Sold / Revenue
=1 - 354.948 / 364.339
=2.58 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.


American Oncology Network COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of American Oncology Network's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


American Oncology Network (American Oncology Network) Business Description

Traded in Other Exchanges
Address
10485 NE 6th Street, Unit 3930, Bellevue, WA, USA, 98004
American Oncology Network Inc Formerly American Oncology Network LLC is an alliance of physicians and seasoned healthcare leaders who provide comprehensive oncology services through 24 oncology practices located in Arkansas, Louisiana, Indiana, Virginia, Ohio, Nevada, Iowa, Missouri, Washington, North Carolina, Michigan, Maryland, South Carolina, Arizona, and Georgia. The Company also provides expertise in drug procurement and payor contracting, along with practice diversification through centralized laboratory and pathology services, as well as specialty pharmacy services.